AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05121831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 2
Description: Dose level 2 of DGX-001
Study NCT05121831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 3
Description: Dose level 3 of DGX-001
Study NCT05121831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGX-001 Dose 4
Description: Dose level 4 of DGX-001
Study NCT05121831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD dose panel of DGX-001
Description: Dose levels confirmed through SAD and MAD
Study NCT05307341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
Study NCT05572788 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EUS-guided fine needle aspiration of pancreatic cysts
Description: Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
Study NCT05572788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided fine needle aspiration of pancreatic cysts
Description: Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
Study NCT05690672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Delirium Screening
Description: Either 3D-CAM or 4AT
Study NCT05060172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloomlife MFM-Pro
Description: Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data.
Study NCT05389384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive shoulder exoskeleton
Description: Participants complete overhead working task with support of exo
Study NCT05389384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Description: Participants complete a fatiguing protocol
Study NCT05389384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No exoskeleton support
Description: Exoskeleton is worn, but no support provided
Study NCT05389384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No peripheral fatiguing protocol
Description: Participants complete no fatiguing protocol
Study NCT04687007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-ALD
Description: At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.
Study NCT04687007 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list
Description: At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
Study NCT06173661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fremanezumab
Description: The intervention will be active medication.
Study NCT06173661 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention will be placebo injection.
Study NCT04977973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided programme on body image
Description: Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program.
Study NCT04977973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided programme on cooperation
Description: Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program.
Study NCT06357884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Callus debridement
Description: Eligible patients will be seated on a podiatry couch. Standard skin preparation procedure will be done with 2% Chlorhexidine gluconate in 70% isopropyl cleansing to all areas of feet. The same researcher will perform sharp debridement in all participants to minimize the variance between procedures. The procedure will comply with Infection Control Guideline (Podiatry) . A sterile scalpel handle loaded with a single-use No. 15 blade will be used to carry out sharp debridement using aseptic technique. Hyperkeratotic tissue will be debrided until smooth transition with adjacent skin is achieved and underlying pinkish normal skin is visible. Used scalpel will be unloaded and disposed by a QlickSmart ® BladeFLASK scalpel blade remover.
Study NCT05127291 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dual-task
Description: In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
Study NCT05127291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task
Description: In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
Study NCT04980469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitex negundo + Zingiber officinale
Description: 200 mg/ Capsule
Study NCT04980469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MCC)
Description: 200 mg/ Capsule
Study NCT05207748 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone mineral density
Description: Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
Study NCT05593354 — intervention group
Intervention type: DEVICE
Intervention: Micropulse Transscleral laser therapy
Description: Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
Study NCT05854537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine ganglion block using bupivacaine: xylocaine
Description: Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
Study NCT05854537 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine ganglion block using normal saline
Description: Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
Study NCT05462106 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo
Study NCT05462106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose A
Description: Administration of Dose A of ACI-24.060
Study NCT05462106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose B
Description: Administration of Dose B of ACI-24.060
Study NCT05462106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose C
Description: Administration of Dose C of ACI-24.060
Study NCT05462106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose D
Description: Administration of Dose D of ACI-24.060
Study NCT04924010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format \[Connolly KS et al\] AND an evidence-based CBT manual specifically designed to treat chronic pain \[Murphy JL et al\].
Study NCT04924010 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education and Mindfulness
Description: To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
Study NCT05919316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray
Description: 50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
Study NCT05935241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mPATH
Description: The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.
Study NCT05935241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
Study NCT05318274 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
Study NCT05318274 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated radiotherapy
Description: Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
Study NCT05462106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose X
Description: Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
Study NCT05462106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24.060 at Dose Y
Description: Administration of Dose Y of ACI-24.060
Study NCT05709041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized lung-protective ventilation
Description: Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released.
Study NCT05709041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard lung-protective ventilation
Description: Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
Study NCT05438498 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Evusheld (tixagevimab+cilgavimab) IM or IV
Description: Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
Study NCT04593875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active LIFUP Treatment
Description: Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.
Study NCT04593875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham LIFUP Treatment
Description: The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
Study NCT06085287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Description: Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
Study NCT04166656 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trumenba®
Description: Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
Study NCT04166656 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bexsero®
Description: Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
Study NCT04702256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab administration
Description: Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients.
Study NCT04702256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil
Description: IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients.
Study NCT04702256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of methylprednisolone, paracetamol and dexchlorpheniramine
Description: Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
Study NCT05444426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Rehabilitation
Description: hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
Study NCT04965272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 0.75 mg/day
Description: Oral Capsule
Study NCT04965272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Description: Oral Capsule
Study NCT04965272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0 mg/day
Description: Oral Capsule
Study NCT04965272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT05066958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: boost anti-viral immunity after T-cell depleted HSCT
Description: * Registration and informed consent sign~* Screening clinical and laboratory examination, assessment of compliance with inclusion criteria~* Survey of the recipient and potential donors~* Donor selection~* The study of the immune response to relevant antigens in the donor and recipient~* Pre-transplant conditioning~* Stimulation of the donor and apheresis of peripheral blood mononuclear cells~* Graft processing~* The manufacturing of cell product~* Transplant Infusion~* Antigen-primed memory DLI infusion~* Inpatient care until day +30~* Outpatient monitoring and screening
Study NCT06449859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2938 Injection
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Study NCT06449859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC2938 Placebo
Description: TQC2938 Placebo is a placebo comparator
Study NCT05618132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acetylcholine rechallenge
Description: STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm).
Study NCT06377072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenqi Sherong Pill
Description: two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
Study NCT06377072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
Study NCT05767372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coherent Breathing Exercise
Description: Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths.
Study NCT05517486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-101
Description: Bupivacaine HCl metered spray
Study NCT05517486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl subcutaneous injection
Description: Bupivacaine HCl, 50 mg/10 mL